Rapid, Field Deployable COVID-19 Testing
- Funded by University of Minnesota
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19start year
-99Known Financial Commitments (USD)
$0Funder
University of MinnesotaPrincipal Investigator
PhD. Mark OsbornResearch Location
United States of AmericaLead Research Institution
Medical School, University of MinnesotaResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The current lack of expeditious testing for COVID-19 represents a critical diagnostic and therapeutic gap. This study led by Mark Osborn, PhD, assistant professor of pediatrics, will determine if a rapid, point of care system operative in his lab can be rapidly adapted and deployed as part of a field-based COVID-19 diagnostic platform that does not require specialized techniques or equipment. "Our assay will be designed to rapidly test for COVID-19 and then further distinguish between COVID-19 Type I and Type II," said Osborn. Type II COVID is believed to be more infectious, so the ability to discriminate between Types I and II can not only help prioritize patients for urgent care, it can provide important information for epidemiologists and policy makers. "Using rapid nucleic acid isolation, amplification, and detection with our design will give results in one hour. This streamlined approach will help in easing the current test backlog and will be a valuable public health resource, especially in areas where advanced medical and diagnostic infrastructure is not present," said Osborn.